LINC01432: A Drug Target / Disease Biomarker (G100270679)

Target Name: LINC01432

NCBI ID: G100270679

LINC01432

Other Name(s): Long intergenic non-protein coding RNA 1432 | long intergenic non-protein coding RNA 1432

LINC01432: A Drug Target / Disease Biomarker

LINC01432 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the regulation of inflammation and immune responses.

One of the most promising aspects of LINC01432 is its potential as a drug target. Several studies have identified potential binders for LINC01432, including small molecules, peptides, and even proteins. These binders have been shown to interact with LINC01432 and to modulate its activity, suggesting that they may be useful in treating a variety of diseases.

One of the most promising aspects of LINC01432 is its potential as a drug target for multiple sclerosis (MS). MS is a progressive disease that affects the central nervous system and is characterized by the destruction of nerve cells. There is currently no cure for MS, and several treatments are available, but they are often limited in their effectiveness and can have significant side effects.

LINC01432 has been shown to be involved in the regulation of the immune response, which is a key aspect of MS. Several studies have shown that LINC01432 plays a role in the regulation of T cell function, which is a critical part of the immune response. In addition, LINC01432 has been shown to regulate the production of antibodies, which are also involved in the immune response.

Another promising aspect of LINC01432 is its potential as a drug target for cancer. Several studies have shown that LINC01432 plays a role in the regulation of cell growth and division, which are critical aspects of cancer development. In addition, LINC01432 has been shown to interact with several proteins that are involved in the regulation of cancer, including the TGF-β pathway.

In addition to its potential as a drug target, LINC01432 has also been shown to have potential as a biomarker. Several studies have shown that LINC01432 can be used as a biomarker for a variety of diseases, including MS, cancer, and neurodegenerative diseases. In addition, LINC01432 has been shown to be expressed in several types of cancer, which suggests that it may be a useful biomarker for these diseases.

Overall, LINC01432 is a protein that has the potential to be a drug target for a variety of diseases. Its function is not well understood, but it is known to play a role in the regulation of inflammation and immune responses. Further research is needed to fully understand its potential as a drug target and to develop effective treatments for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 1432

The "LINC01432 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01432 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets